Squarepoint’s BioAtla BCAB Stock Holding History

Squarepoint’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-600	Closed	-$17.7K	–	4580
2024 Q4	$17.7K	Buy	+600	New	+$50.4K	﹤0.01%	4943
2024 Q2	–	Sell	-1,850	Closed	-$318K	–	4056
2024 Q1	$318K	Buy	+1,850	New	+$230K	﹤0.01%	3341

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Squarepoint's BCAB Position: Q2 2025 in Review

Squarepoint sold out of BioAtla (BCAB) in Q2 2025, closing a stake of 5,205 shares — an estimated $90.3K sold.

Squarepoint first reported a position in BCAB in Q2 2021 and held it in 9 quarters. The position peaked at $525K in Q1 2022. 39 funds tracked by Wall St. Rank hold BCAB as of Q2 2025.

Squarepoint reported no remaining BioAtla position as of Q2 2025 after selling out during the quarter.
Squarepoint sold 5,205 BioAtla shares in Q2 2025, an estimated $90.3K.
Squarepoint first reported a position in BioAtla in Q2 2021 and held it in 9 quarters.
Squarepoint's BioAtla position peaked at $525K in Q1 2022.
39 funds tracked by Wall St. Rank held BioAtla as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.